# Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

> **NCT03760575** · PHASE1 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Mesotheliomas Pleural

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Indocyanine Green (ICG) Image-Guided Surgery
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03760575
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-10
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760575, "Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03760575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*